Inducible and conditional knockout (icKO) of ERK5 decreases adult OB neurogenesis. by Tan Li (404990)

Tethered HP1 Decreases Histone Acetylation throughout the ψVλ Array by W. Jason Cummings (9607)

FABP5 overexpression decreases inflammation and increases innate immunity in primary NHBE cells. by Fabienne Gally (260470)

“…<p><b>A.</b> CS exposure decreases <i>P. aeruginosa</i> colony forming units (CFU) on primary NHBE cells overexpressing FABP5. …”

PFKFB3-4+5 knockdown leads to decreased cell growth and colony formation. by Ulli Heydasch (11091062)

Knockdown of endogenous Cdk-5 decreases T-type Ca2+ channel functional expression. by Aida Calderón-Rivera (701054)

Troglitazone decreases α5 integrin-dependent cell adhesion in K562 cells. by Amanda M. Hanson (543116)

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b - Fig 1 by Nobuyuki Matsumoto (239090)

Subjects:

Circulating CXCR5+CD4+ Tfh cells are significantly decreased in HCC patients. by Yiqiong Jia (692871)

Overexpression of PR decreases Myc expression and activity. by Tamar Kavlashvili (849072)

Cardamonin decreased the expression of lipogenic proteins. by Peiguang Niu (17044532)

Distribution of pulmonary ventilation assessed by center of ventilation (CoV) presented over the five time points: Induction-SB, MV-5min, MV-30min, MV-late and recovery-SB. by Milena S. Nascimento (14803681)

VAMP2 decreases 5-HT uptake and SERT cell surface expression in HEK-293 MSR cells by reducing the delivery rate of the transporter to the plasma membrane. by Heidi Kaastrup Müller (570207)

Unusual [3+1] Cycloaddition of a Stable Silylene with a 2,3-Diazabuta-1,3-diene versus [4+1] Cycloaddition toward a Buta-1,3-diene by Yun Xiong (1403545)

Subjects:

VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10^-5), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10^-5), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10^-22), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10^-71), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10^-28), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10^-12), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10^-10) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10^-17). …”

Clinical characteristics. by Jesse A. Davidson (3158913)

Subjects:

13C5-adenosine production with ex vivo alkaline phosphatase supplementation. by Jesse A. Davidson (3158913)

Subjects:

Correlation of AP activity to 13C5-adenosine production pre-operation and prior to separation from cardiopulmonary bypass. by Jesse A. Davidson (3158913)

Subjects:

Pre-operation to rewarming change in alkaline phosphatase activity versus change in 13C5-adenosine with CD73 inhibition. by Jesse A. Davidson (3158913)

Subjects:

Pre-operation to rewarming change in alkaline phosphatase activity versus change in 13C5-adenosine without CD73 inhibition. by Jesse A. Davidson (3158913)

Subjects:

13C5-adenosine production without ectonucleotidase inhibition, with CD73 inhibition, and with alkaline phosphatase inhibition. by Jesse A. Davidson (3158913)

Subjects: